INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

    loading  Checking for direct PDF access through Ovid

Abstract

Background

A randomized trial conducted by the ECOG showed that intensification of induction therapy using a high daily dose of daunorubicin (90 mg/m2/d x 3d) improved both complete remission (CR) rate and survival duration compared with those of young adults with acute myeloid leukemia (AML) receiving standard daunorubicin dose (45 mg/m2/d x 3d) (Fernandez HF et al. N Engl J Med 2009;361:1249). We also conducted a randomized trial comparing two different doses of daunorubicin as induction chemotherapy in young adults with AML (Lee JH et al. Blood 2011;118:3832).

Methods

Of 383 patients who were analyzed, 189 received standard-dose daunorubicin (SD-DN, 45 mg/m2/d x 3d) and 194 received high-dose daunorubicin (HD-DN, 90 mg/m2/d x 3d) in addition to cytarabine (200 mg/m2/d x 7d) to induce CR.

Results

The CR rates were 72.0% in SD-DN arm and 82.5% in HD-DN arm. At a median follow-up time of 52.6 months, overall (OS) and event-free (EFS) survival were higher in HD-DN arm than in SD-DN arm (OS, 46.8% versus 34.6%; EFS, 40.8% versus 28.4%). Differences in CR rate and both OS and EFS remained significant after adjustment for other variables (CR, HR, 1.802, P = 0.024; OS, HR, 0.739, P = 0.032; EFS, HR, 0.774, P = 0.048).

Conclusions

Given the results of both our study and the ECOG work, high-dose daunorubicin (90 mg/m2/d) for 3 days should be the future standard of care for induction of patients with AML. However, it is not known whether a dose of 90 mg/m2/d is superior to a dose of 45–90 mg/m2/day. It is also necessary to compare the effects of high-dose daunorubicin with that of other agents, especially idarubicin. For these reasons, we began another randomized trial comparing two induction regimens in young adults with AML: high-dose daunorubicin (90 mg/m2/d x 3d) versus idarubicin (12 mg/m2/d x 3d) in addition to cytarabine (200 mg/m2/d x 7d). This study is now recruiting patients and the results of interim analysis will be presented at the 10th annual meeting of Japanese Society of Medical Oncology.

Related Topics

    loading  Loading Related Articles